BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development.

Under the joint research project, a new research team will be set up at the BioMed X Institute in Heidelberg, Germany.

This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

The companies will jointly create a virtual patient engine for the drug candidates’ clinical translation.

The partnership intends to address a 90% failure rate of new therapy candidates in clinical development, which is a key bottleneck of the pharmaceutical industry. 

For the project, deep datasets and capabilities of Sanofi will be leveraged to potentially transform the practice of medicine using digital data and AI.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As proof-of-concept (PoC), chronic immune-mediated diseases such as atopic dermatitis (AD) and inflammatory bowel disease (IBD) will be the focus areas of the preliminary model.

BioMed X Institute founder and managing director Christian Tidona said: “Our new collaboration with Sanofi allows us to further extend our data science and AI expertise in Heidelberg, where we have developed an ideal incubation environment for biomedical innovation at the interface between academia and industry.”

The companies will select a varied group of skilled researchers for the project.

The new group will become part of the 11 research teams at the BioMed X Institute, currently utilising complicated human ex-vivo models and data science in oncology, immunology, and neuroscience regions.

Sanofi Research global head and chief scientific officer Frank Nestle said: “This groundbreaking research collaboration will allow us to partner with scientists with unique computational skills and diverse capabilities that will help us to achieve our goals of bringing vital treatments to patients with chronic inflammatory diseases. 

“This collaboration will be instrumental for advancing with our core mission of transforming drug discovery and development through the application of AI-based modelling and simulation.”

The latest development comes after Sanofi US and Provention Bio entered a co-promotion agreement to launch the latter’s teplizumab for the delay in the onset of clinical type 1 diabetes.